What is your preferred third line approach for a patient with refractory small cell lung cancer who has failed second line therapy with nivolumab after recieving first line platinum based therapy ?

1 Answers

Mednet Member

Medical Oncology · University of Minnesota

I would prefer a clinical trial or perhaps a taxane, but I have added ipilimumab to nivolumab in this situation, despite the lack of data. The results remain to be seen!